台股 » 個股 » 生展 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

生展

(8279)
  • 股價
    150.0
  • 漲跌
    ▼1.0
  • 漲幅
    -0.66%
  • 成交量
    11
  • 產業
    上櫃 生技醫療類股▼0.47%
  • 68人加入追蹤

    立即追蹤

  • 本地時間:13:30

     
生展 (8279)籌碼相關-台中銀-豐原 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

台中銀-豐原 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2024/04/291154.5000.00154.001109.58%
2024/02/295150.0000.00152.005954.55%
2023/04/2800.001195.00191.00-154-1.82%
2023/04/181181.0000.00180.001472.09%
2023/03/0300.001172.00171.00-158-1.72%
2023/02/231167.5000.00166.001581.72%
2022/12/1600.001150.50151.50-161-1.63%
2022/12/151150.5000.00150.501601.65%
2022/12/0800.001156.50156.50-158-1.72%
2022/12/061153.001150.00149.500610.00%
2022/12/052151.501153.50151.001611.64%
2022/12/021146.002150.00148.50-161-1.64%
2022/11/182146.501143.00143.501751.33%
2022/11/1700.001148.00149.50-174-1.34%
2022/11/161137.0000.00136.001741.34%
2022/08/3100.001.1177.27175.00-1.195-1.15%
2022/04/2100.0025130.00131.00-2568-36.48%
2022/04/1800.0012128.58129.50-1267-17.80%
2022/04/1200.003128.00127.00-367-4.47%
2022/02/1800.0010132.00131.00-1068-14.51%
2022/02/1700.0010131.00130.50-1068-14.63%
2022/02/0700.0010131.00131.00-1062-16.01%
2022/01/2520129.2300.00128.00205635.13%
2022/01/2000.0030128.00128.00-3045-65.34%
2021/06/2500.001107.50107.00-140-2.47%
2021/06/111106.5000.00106.001382.57%
2020/12/1500.001110.00108.50-132-3.10%
2020/11/171113.0000.00113.001452.19%
2020/08/1000.002127.00129.00-296-2.07%
2020/08/0600.0012.1127.50127.50-12.181-14.79%
2020/08/0400.001115.00115.50-172-1.39%
2020/07/1600.001119.50119.50-175-1.32%
2020/07/081114.5000.00114.001661.50%
2020/06/121111.5000.00111.501681.46%
2020/06/0400.001114.50115.00-178-1.28%
2020/06/031111.5000.00114.501931.07%
2020/05/201109.0000.00111.001931.07%
2020/04/0600.00187.0087.50-187-1.15%
2020/04/01184.9000.0085.201861.16%
2020/03/12199.0000.00100.001781.28%
2019/12/3100.001118.00117.50-168-1.46%
2019/12/301117.5000.00117.501691.45%
2019/12/1000.001115.50116.50-169-1.44%
2019/12/091115.0000.00115.001691.44%
2019/11/1200.001115.50116.00-159-1.68%
2019/10/151126.0000.00126.001921.08%
2019/10/081130.5000.00129.001941.06%
2019/09/191137.5000.00138.5011140.87%
2019/09/0300.001144.50143.00-1114-0.87%
2019/09/021144.0000.00144.0011150.87%
2019/08/2800.001141.00141.00-1111-0.90%
2019/08/271137.5000.00137.0011090.91%
2019/08/2100.001136.50138.50-1107-0.93%
2019/08/191135.0000.00135.0011060.94%
2019/08/1500.001134.50137.00-1104-0.95%
2019/08/121139.5000.00139.5011020.98%
2019/07/2500.001153.50153.50-186-1.15%
2019/07/0800.001141.00141.00-159-1.68%
2019/07/051146.0000.00145.501581.70%
2019/07/0200.001.1138.91139.00-1.155-1.97%
2019/05/1400.001118.00119.00-166-1.50%
2019/05/131119.5000.00119.501661.50%
2019/05/101123.5000.00124.001661.51%
2019/04/1800.001117.00117.50-157-1.73%
2019/04/101119.5000.00119.501531.85%
2019/02/2000.001103.50103.00-125-3.89%
2019/01/11196.7000.0096.101214.68%
2018/12/2400.001100.0099.40-135-2.84%
2018/12/0300.000.199.7099.60-0.143-0.23%
2018/07/103120.0000.00119.5031931.55%
2018/06/151149.0000.00149.0012820.35%
2018/05/031167.0000.00163.0013670.27%
2018/04/261164.0000.00156.5013660.27%
2018/04/1700.001152.50152.00-1325-0.31%
2018/04/1200.001157.50158.50-1335-0.30%
2018/04/111158.0000.00158.0013330.30%
2018/04/1000.001157.00155.00-1332-0.30%
2018/04/031170.5010170.00167.50-9315-2.86%
2018/03/3000.0011154.05151.00-11282-3.89%
2018/03/2911144.001147.50147.50102703.69%
2018/03/214144.504145.75143.0002670.00%
2018/03/081142.5000.00137.0012930.34%
2018/02/2300.003134.50133.50-3312-0.96%
2018/02/223133.0000.00133.0033140.95%
2018/02/124138.5000.00136.0043011.33%
2018/02/0917148.7100.00151.00172915.83%
2018/01/261177.501180.50179.5003210.00%
2018/01/2200.0012172.13172.50-12313-3.82%
2018/01/167169.0700.00168.0072942.38%
2018/01/1500.002165.50167.00-2290-0.69%
2018/01/121161.0000.00160.0012860.35%
2018/01/111164.0000.00162.5012850.35%
2018/01/102168.5000.00166.5022850.70%
2018/01/091171.5000.00172.5012810.36%
2018/01/0400.001153.50156.00-1269-0.37%
〈國光生展望〉子公司安特羅腸病毒三期臨床入尾聲 明年展開IPOAnue鉅亨-2023/12/26
〈國光生展望〉流感疫苗申請巴西藥證+破傷風切新市場 外銷業績拚成長Anue鉅亨-2023/12/26
〈聯合再生展望〉洪傳獻:TOPCon技術明年成主流 獲利表現佳Anue鉅亨-2023/10/16
生展 相關文章